Loading...
01/10 16:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: a 3% net sales decline, significant losses in China, a net loss for fiscal 2024, and declining gross margins. The lack of a shareholder return plan and elevated inventory levels further dampen sentiment. Despite some optimism about future growth and the U.S. market, the Q&A session highlights uncertainties, particularly regarding competition and revenue recognition. The market cap suggests a moderate reaction, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.
Net Sales $313,900,000, a decline of 3% compared to $322,400,000 in fiscal 2023, primarily impacted by a significant decline in ICL sales in China due to weak consumer confidence and economic conditions.
ICL Sales Outside of China $152,000,000, growth of 1713% in the fourth quarter and fiscal 2024, driven by solid returns on investments and execution against strategic priorities.
ICL Sales in China (Q4) $7,500,000, down 13% year over year, impacted by a $27,500,000 order shipped in December for which revenue was not recognized due to extended payment terms.
ICL Sales in China (Full Year) $161,000,000, down 13% year over year, primarily due to weak consumer confidence and a significant order that was not recognized as revenue.
Net Loss $20,200,000 for fiscal 2024, compared to net income of $21,300,000 in fiscal 2023, driven by declines in sales, particularly in China.
Gross Margin 76.3%, down 210 basis points year over year, impacted by costs related to the December shipment to China and expansion of manufacturing capabilities.
Cash Position $230,500,000 at the end of fiscal 2024, compared to $232,400,000 at the beginning of the year, indicating stable cash reserves despite operational challenges.
Adjusted EBITDA Loss Approximately $50,000,000 to $15,000,000 for fiscal 2025, with a loss per diluted share range of approximately $1 to $0.30, reflecting anticipated challenges in revenue generation.
Capital Expenditures Approximately $15,000,000 for fiscal 2025, primarily related to completing manufacturing expansion and technology infrastructure improvements.
EVO Plus Launch: The company anticipates the launch of EVO Plus in China in mid-2025, which is expected to drive incremental pricing power and potential revenue upside.
ICL Sales Growth Outside China: ICL sales outside of China reached $152 million, reflecting a growth of 1713% in the fourth quarter and fiscal year 2024.
China ICL Sales Outlook: For fiscal 2025, STAAR expects China ICL sales in the range of $75 million to $125 million, acknowledging the uncertainty in the market.
Overall Refractive Market Outlook: The overall refractive market in China is projected to decline by 10% at the low end and potentially grow by 10% at the high end.
Operational Efficiencies: The company plans to manage working capital and implement cost-cutting measures, including lowering production output and reducing capital expenditures.
Manufacturing Expansion: STAAR has made significant investments in manufacturing capacity expansion, particularly in Switzerland, to support future growth.
Shift in Sales Strategy: STAAR is shifting its focus to incentivize sell-through rather than sell-in to distributors, aiming to improve demand creation and execution.
Market Share Gains: Despite challenges in China, STAAR has continued to gain market share in other regions, with a 22% growth in the U.S. and 20% growth in APAC excluding China.
China Economic Slowdown: The company reported a significant negative impact on sales due to weak macroeconomic conditions in China, particularly in the fourth quarter of fiscal 2024. Consumer sentiment and spending in China remain at unprecedented low levels, affecting demand for ICLs.
Inventory Management Issues: A $27,500,000 order shipped to China was not recognized as revenue due to extended payment terms requested by a distributor, leading to elevated inventory levels and impacting financial results.
Volatility in Procedural Volumes: The company anticipates continued volatility in procedural volumes in China until consumer confidence stabilizes. The correlation between sell-through data and macroeconomic conditions in China is a significant concern.
Regulatory and Competitive Pressures: The entry of new competitors, such as Eyebright, into the market could impact sales, although the company believes it is well-positioned to maintain its market share.
Economic Factors: The company's outlook for fiscal 2025 includes a wide range for ICL sales in China, reflecting uncertainty in consumer confidence and potential government stimulus effects.
Cash Flow and Operating Expenses: The company expects to manage cash flow carefully, with anticipated cash burn due to lower revenue forecasts and elevated inventory levels, while also planning to implement cost-cutting measures.
Geopolitical Risks: Potential impacts from geopolitical tensions and tariffs are acknowledged, but the company believes it is insulated due to its manufacturing capabilities and sourcing strategies.
ICL Sales Growth Outside China Q4 2024: STAAR generated $152,000,000 of ICL sales outside of China, which is growth of 1713% in the fourth quarter.
Highway 93 and FastLane Commercial Strategies: The U.S. sales growth of 22% and unit growth of 21% were attributed to the execution of these strategies.
FastLane Initiative: FastLane customers generated sales growth of 45% in fiscal 2024 compared to 2023.
EVO Plus Launch: The anticipated launch of EVO Plus in China in 2025 is expected to drive incremental pricing power.
Focus on Sell Through: The company is shifting focus to incentivize sell through rather than sell in to distributors.
ICL Sales Outlook FY 2025 (Excluding China): Anticipated ICL sales of $165,000,000 to $175,000,000, representing growth of 9% to 15%.
China ICL Sales Outlook FY 2025: Expected range of $75,000,000 to $125,000,000, with assumptions of market recovery.
Gross Margin Expectations: First half gross margins expected to be in the low 70s, second half in the mid to high 70s, resulting in a full year gross margin of approximately 75%.
Adjusted EBITDA Outlook FY 2025: Anticipated adjusted EBITDA loss of approximately $50,000,000 to $15,000,000 for the year.
CapEx Guidance FY 2025: Total CapEx spend expected to be approximately $15,000,000, primarily for manufacturing expansion and technology improvements.
Shareholder Return Plan: STAAR Surgical has not announced a specific Shareholder Return Plan, including a share buyback program or dividend program, during this call.
The earnings report shows significant declines in net sales and gross margin, especially in China, and an EBITDA loss. The Q&A reveals management's unclear responses regarding competition impact and withdrawn guidance, causing analyst concern. Despite some positive developments in ICL sales and market strategy, the lack of a share repurchase program and restructuring charges further weigh negatively. Given the market cap, the negative aspects are likely to outweigh the positives, leading to a negative stock price reaction.
The earnings call revealed significant challenges: a massive decline in sales, especially in China, and a drop in gross margin. Despite some optimism about future demand and cost optimization, the withdrawal of guidance due to economic uncertainty and competitive pressures add to investor concerns. The lack of a shareholder return plan and refusal to provide clear guidance further dampen sentiment. Given the small market cap, these factors are likely to result in a negative stock price movement over the next two weeks.
The earnings call reveals several concerns: a 3% net sales decline, significant losses in China, a net loss for fiscal 2024, and declining gross margins. The lack of a shareholder return plan and elevated inventory levels further dampen sentiment. Despite some optimism about future growth and the U.S. market, the Q&A session highlights uncertainties, particularly regarding competition and revenue recognition. The market cap suggests a moderate reaction, leading to a prediction of a negative stock price movement of -2% to -8% over the next two weeks.
The earnings call presents mixed signals. Financial performance shows growth in sales and net income, but declining gross margins and increased expenses raise concerns. The Q&A reveals challenges in China and the U.S. market, with management hesitant to provide clear guidance. The lack of a shareholder return plan and macroeconomic uncertainties also weigh on sentiment. Despite some positives, such as market share gains, the overall outlook remains uncertain, leading to a neutral prediction for stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
